MBX Biosciences surges after mid-stage trial win for hormone disorder drug

** Shares of drug developer MBX Biosciences MBX.O more than double to $24.96

** MBX says its once-weekly experimental drug, canvuparatide, met main goal in mid-stage trial for adults with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels

** In 12-week study, 63% of patients on canvuparatide kept calcium in normal range without needing active vitamin D or more than 600 mg of daily calcium supplements, compared with 31% on placebo, difference of which was statically significant

** The drug was well tolerated with no serious adverse events, company says

** MBX plans to start late-stage trial in 2026

** Including session's move, MBX stock up 19.4% YTD